The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000602325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/03/2026
Date registered
Help: Date registered
13/05/2026
Date last updated
Help: Date last updated
13/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Testing a new lightweight brain scanner (the Micro-X Stroke Scanner) for detecting brain conditions that affect stroke treatment decisions in hospitalised patients.
Scientific title
The Micro-X Stroke Scanner: A prospective multi-centre pilot study of a novel miniaturised cone beam computed tomography scanner for identifying neuroimaging-based contraindications to stroke thrombolysis in hospitalised patients.
Additional trial identifiers [1] 316871 0
Melbourne Health – 2025.239
Universal Trial Number (UTN)
Trial acronym
MXS-Pilot
Related trial records

Health condition
Health condition(s) studied:
Ischaemic stroke 341264 0
Intracranial haemorrhage 341265 0
Brain tumour 341266 0
Stroke mimic 341267 0
Condition category
Condition code
Stroke 337341 337341 0 0
Ischaemic
Stroke 337342 337342 0 0
Haemorrhagic
Cancer 337343 337343 0 0
Brain
Neurological 337344 337344 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Micro-X Stroke Scanner (MXS) cone beam CT brain scan

The MXS is a miniaturised cone beam computed tomography brain scanner using carbon nanotube X-ray technology. The scanner is substantially lighter than existing brain CT scanners and uses 21 carbon nanotube X-ray sources with a curved X-ray detector to acquire whole-of-brain images.

Each participant will undergo one MXS brain scan, performed as soon as possible before or after their hospital-grade CT, at the local team's discretion. The participants' clinical conditions are already known prior to undergoing the MXS and CT scans. Each pathology group will be assessed separately without direct comparison.

The MXS scan will not be used to guide clinical decision-making. Images will be independently evaluated by 20 readers (10 expert, 10 standard) for the presence of neuroimaging-based contraindications to stroke thrombolysis.

Duration: Each MXS scan takes approximately 2 minutes.

Administration: The MXS scan will be performed by a trained radiographer.

Stage 1.1 (qualitative run-in): The first 10 evaluable participants' MXS scans are assessed by 5 expert readers for diagnostic image quality. If consensus is reached that quality is sufficient, the study proceeds.

Stage 1.2 (quantitative run-in): The first 20 paired scans (MXS + hospital CT) are evaluated by 10 expert readers for inter-modality agreement (? = 0.9 threshold). This stage is analysed descriptively to confirm feasibility and does not contribute to the primary endpoint.

Stage 2 (standard reader evaluation): An additional 10 standard readers independently evaluate the paired scans and report intracranial pathology.

Adherence: As the intervention comprises a single MXS brain scan per participant, adherence is assessed by successful completion of the scan. Scan completion and quality will be confirmed at the time of acquisition, and any technical failures or incomplete scans will be recorded in the electronic Case Report Form (REDCap). Image quality will also be formally assessed by expert readers at the Stage 1.1 qualitative checkpoint.

Intervention code [1] 333571 0
Diagnosis / Prognosis
Intervention code [2] 333748 0
Treatment: Devices
Description of the comparator or control
Hospital-grade non-contrast CT brain scan (Siemens SOMATOM Definition Edge, Siemens Force, or Aquilion ONE). Each participant undergoes both the MXS scan and hospital-grade CT in a within-participant crossover design. The hospital-grade CT serves as the reference standard against which MXS imaging outputs are compared.

Imaging-pair timing: To ensure pathophysiologic comparability while maintaining operational feasibility, the MXS scan will be obtained within 12 hours before or after the hospital CT for acute stroke pathologies (ischaemic stroke, ICH, SAH, IVH), provided this does not delay standard care, and that no significant difference in radiological findings would be anticipated based on clinical grounds. Clinical stability between scans will be documented. For non-acute categories (SDH, intra-axial tumour, stroke mimics), the MXS scan may be obtained within 72 hours of the reference CT. The exact CT?MXS interval (minutes) will be recorded for all participants.
Control group
Active

Outcomes
Primary outcome [1] 344861 0
Agreement between the Micro-X Stroke Scanner (MXS) and hospital-grade CT in identifying neuroimaging-based contraindications to stroke thrombolysis.
Timepoint [1] 344861 0
At the time of MXS and hospital-grade CT scanning during the index hospital admission
Secondary outcome [1] 459541 0
Agreement in classifying recent established ischaemic stroke
Timepoint [1] 459541 0
At the time of scanning during index admission
Secondary outcome [2] 459542 0
Agreement in classifying recent intracerebral haemorrhage
Timepoint [2] 459542 0
At the time of scanning during index admission
Secondary outcome [3] 459543 0
Agreement in classifying recent subarachnoid haemorrhage
Timepoint [3] 459543 0
At the time of scanning during index admission
Secondary outcome [4] 459544 0
Agreement in classifying recent intraventricular haemorrhage
Timepoint [4] 459544 0
At the time of scanning during index admission
Secondary outcome [5] 459545 0
Agreement in classifying subdural haemorrhage
Timepoint [5] 459545 0
At the time of scanning during index admission
Secondary outcome [6] 459546 0
Agreement in classifying intra-axial primary or metastatic brain tumour
Timepoint [6] 459546 0
At the time of scanning during index admission
Secondary outcome [7] 459547 0
Anatomical imaging quality
Timepoint [7] 459547 0
At the time of scanning during index admission
Secondary outcome [8] 459548 0
Image artifact
Timepoint [8] 459548 0
At the time of scanning during index admission
Secondary outcome [9] 459549 0
Safety of MXS imaging
Timepoint [9] 459549 0
At the time of scanning and throughout study participation

Eligibility
Key inclusion criteria
Adults aged 18 years or older.
Individuals admitted to hospital who, at the time of scanning, have (a) known neuroimaging-based contraindications to stroke thrombolysis, or (b) acute focal neurological symptoms with normal CT brain imaging.
Individuals who have a clinical indication to undergo hospital-based CT, or who have consented to undergo an additional non-contrast CT scan in whom the potential risk of additional radiation dose is deemed acceptable.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Administration of intravenous or intra-arterial iodinated contrast less than 24 hours prior to MXS imaging.
Unable to lie still for the duration of the scan.
Any contraindications to CT scan.
Unable to have the MXS performed within the pre-specified timeframes.
Participant is pregnant.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Sample size: 108 participants (27 per pathology category plus 9 stroke mimics), increased from 90 to allow for 20% dropout or device failure. Sample size provides >0.9 power to reject the null hypothesis of poor agreement (Cohen's kappa = 0.4) in favour of near-perfect agreement (kappa = 0.9), with two-sided alpha of 0.05, using the Donner and Eliasziw goodness-of-fit approach. Each scan is read by 20 readers (10 expert, 10 standard). Primary analysis estimates Cohen's kappa for inter-modality agreement from the Stage 3 validation cohort. Secondary analyses include sensitivity, specificity, and accuracy for each pathology subtype, stratified by reader experience. Feasibility and safety analyses will assess scan completion rates and radiation dose. A pre-specified Statistical Analysis Plan will be finalised prior to database lock.

Participants’ clinical conditions are known prior to undergoing the MXS scan. Participants are enrolled on the basis of having known neuroimaging-based contraindications to stroke thrombolysis (identified on prior hospital imaging), or having presented with acute focal neurological symptoms and a normal CT brain. However, all readers (both expert and standard) are blinded to the pathology type and imaging modality during their assessments.

Outcomes will be assessed both across all pathology groups combined (for the primary endpoint: overall agreement in identifying any neuroimaging-based contraindication to thrombolysis) and for each pathology subtype separately (as secondary endpoints – e.g., agreement for ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, intraventricular haemorrhage, subdural haematoma, and brain tumour individually).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 29306 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [2] 29307 0
The Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 45624 0
3050 - Parkville
Recruitment postcode(s) [2] 45625 0
5000 - Adelaide

Funding & Sponsors
Funding source category [1] 321469 0
Government body
Name [1] 321469 0
Department of Health and Aged Care — Medical Research Future Fund (MRFF) Frontier Health and Medical Research Initiative
Country [1] 321469 0
Australia
Primary sponsor type
Government body
Name
Melbourne Health
Address
Country
Australia
Secondary sponsor category [1] 324218 0
Commercial sector/Industry
Name [1] 324218 0
Micro-X Ltd
Address [1] 324218 0
Country [1] 324218 0
Australia
Other collaborator category [1] 283883 0
Commercial sector/Industry
Name [1] 283883 0
Micro-X Ltd
Address [1] 283883 0
Country [1] 283883 0
Australia
Other collaborator category [2] 283884 0
Other Collaborative groups
Name [2] 283884 0
Australian Stroke Alliance
Address [2] 283884 0
Country [2] 283884 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320002 0
The Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 320002 0
Ethics committee country [1] 320002 0
Australia
Date submitted for ethics approval [1] 320002 0
28/07/2025
Approval date [1] 320002 0
02/02/2026
Ethics approval number [1] 320002 0
HREC/121206/MH-2025

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149106 0
Dr Anna Balabanski
Address 149106 0
Melbourne Brain Centre at the Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050
Country 149106 0
Australia
Phone 149106 0
+61 3 9342 4424
Fax 149106 0
Email 149106 0
Contact person for public queries
Name 149107 0
Anna Balabanski
Address 149107 0
Melbourne Brain Centre at the Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050
Country 149107 0
Australia
Phone 149107 0
+61 3 9342 4424
Fax 149107 0
Email 149107 0
Contact person for scientific queries
Name 149108 0
Anna Balabanski
Address 149108 0
Melbourne Brain Centre at the Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050
Country 149108 0
Australia
Phone 149108 0
+61 3 9342 4424
Fax 149108 0
Email 149108 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: This is a first-in-human pilot study of a novel device under commercial development. Individual participant imaging data contain potentially identifiable neuroimaging and cannot be shared without comprehensive de-identification. Data access may be considered on a case-by-case basis following publication of study results by contacting the principal investigator.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.